Tenosynovial Giant Cell Tumor Market size is expected to reach USD 11 Billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of tenosynovial giant cell tumor was over USD 8 Billion. The market will notice this surge primarily due to the rising cases of tenosynovial giant cell tumors in people across the globe. In fact, recently 43 in 1 million people got tenosynovial giant cell tumors. Women are slightly more prone to have tenosynovial giant cell tumors in contrast to men whereas the prevalence of these tumors is majorly shown in young people. People between the age of 25 to 50 have tenosynovial GCT and 1 in 2 people with a bone GCT are in their 30s or 40s.
However, the awareness among people worldwide to address the disease and treat it will further wheel the tenosynovial giant cell tumor market and take it to the expected USD by the end of 2036. A global agreement meeting was carried out on June 21, 2022, in Frankfurt, Germany, including global multidisciplinary sarcoma specialists in cooperation with patient representatives from the Sarcoma Patient Advocacy Global Network (SPAGN) to explain the best clinical practice in TGCT and produce the suggestions exhibited herein. Moreover, recent research made by the National Cancer Institute’s (NCI) branch named Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) has shown a treatment journey of D-TGCT patients as a 2-year data-based follow-up and came to know that people internationally are becoming more aware of the disease recently. Most patients suffering from TGCT are young and, although generally not life-forbidding, the disease and its treatment may influence quality of life (QoL).
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
∼5% |
|
Base Year Market Size (2023) |
~USD 8 Billion |
|
Forecast Year Market Size (2036) |
~USD 11 Billion |
|
Regional Scope |
|
Treatment (Drug Therapy, Radiation Therapy, Surgical Procedures)
The surgical procedures segment is anticipated to increase at the fastest CAGR at the time of the forecast period and have around 60% share of the tenosynovial giant cell tumor market. This segment is set to have the largest share due to its frequent use for diagnosing and treating tenosynovial giant cell tumors. Moreover, between 2002 to 2023, 144 patients with D-TGCT experienced surgery as basic treatment with a base age of 39 years. The knee (72%) was the most influenced joint. For 86 patients (60%), surgery was their first TGCT-related treatment and they were reportedly cured. After surgical procedures, high repetition rates are known, with the localized type up to 50% and the diffuse type up to 92%. In massive cases of tenosynovial giant cell tumor, where MRI cannot infer the outcome or offer a verification receipt associating the happening of tenosynovial giant cell tumor in a person, surgical procedures are executed. A biopsy of influenced tissue is studied through surgery to make sure the case of tenosynovial giant cell tumor. Similarly, surgical procedures are frequently executed in the therapy of tenosynovial giant cell tumors and pigmented villonodular synovitis bit by bit revises itself, which takes to repetition post-surgery.
Disease Type (Localized Giant Cell Tumor, Diffuse Giant Cell Tumor)
The localized giant cell tumor segment is projected to control the tenosynovial giant cell tumor market during the forecast period and hold a revenue share of almost 70%. The localized giant cell tumor segment is set to grow and has the largest share as this type of TGCT is more prevalent in people worldwide. For instance, one of the more all-inclusive studies was by Mastboom et al comprising 4,503 cases of TGCT. They noticed that the abundance of tumors was situated locally in the digits (68%) followed by those explained as localized-border (knee, wrist, elbow, hip, etc; 23%), and the rest 9% were diffuse-type tumors. Localized TGCTs emerge chiefly in the hand with roughly 85% of the tumors emerging in the digits. However, the tumors can come at other sites, like the knee, wrist, ankle/foot, and very rarely the elbow or the hip. To understand the patient has localized TGCTs the best process is to make medical imaging.
Our in-depth analysis of the global tenosynovial giant cell tumor market includes the following segments:
|
Disease Type |
|
|
Treatment |
|
|
End-use |
|
North American Market Forecast
The North America region will dominate the global tenosynovial giant cell tumor market and record the largest revenue share of 43 % by the end of 2036. North America is set to hold this position in the coming years because of the inventions and approvals of new novel drugs for tenosynovial giant cell tumors in the region. For instance, on March 23, 2023, Evkeeza is an angiopoietin-like 3 (ANGPTL3) inhibitor shown as a supplement to other low-density lipoprotein-cholesterol (LDL-C) reducing treatments for the cure of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH). Evkeeza is a fully human monoclonal antibody that works by binding to and blocking the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. Evkeeza is the first FDA-licensed ANGPTL3 inhibitor. Evkeeza is directed via intravenous mixture once a month (every 4 weeks).
European Market
However, the Europe tenosynovial giant cell tumor market is poised to grow significantly by the end of 2036. The reason for the growth lies majorly in the government initiatives of the European countries to have novel drugs on TGCT. Recently, SynOx Therapeutics Limited declared its novel monoclonal antibody, emactuzumab, in progress for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been approved as an orphan medicinal material for both localized and diffuse types of the disease by the European Medicines Agency (EMA).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?